Natasha E. Holmes

Natasha E. Holmes

Auto-generated profile, based on publicly available information

Natasha E. Holmes

Mercy Hospital for Women Heidelberg Victoria Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
NHNatasha E. Holmes
Natasha E. Holmes
JTJohn D. Turnidge
John D. Turnidge
WMWendy J. Munckhof
Wendy J. Munckhof
JRJ. Owen Robinson
J. Owen Robinson
TKTony M. Korman
Tony M. Korman
PJPaul D. R. Johnson
Paul D. R. Johnson
A ratio of the vancomycin area under the concentration-time curve to the MIC (AUC/MIC) of ≥400 has been associated with clinical success when treating Staphylococcus aureus pneumonia, and this target was recommended by recently published vancomycin therapeutic monitoring consensus guidelines for treating all serious S. aureus infections. Here, vancomycin serum trough levels and vancomycin AUC/MIC were evaluated in a “real-world” context by following a cohort of 182 patients with S. aureus bacteremia (SAB) and analyzing these parameters within the critical first 96 h of vancomycin therapy. The median vancomycin trough level at this time point was 19.5 mg/liter. There was a significant difference in vancomycin AUC/MIC when using broth microdilution (BMD) compared with Etest MIC (medians of 436.1 and 271.5, respectively; P < 0.001). Obtaining the recommended vancomycin target AUC/MIC of ≥400 using BMD was not associated with lower 30-day all-cause or attributable mortality from SAB ( P = 0.132 and P = 0.273, respectively). However, an alternative vancomycin AUC/MIC of >373, derived using classification and regression tree analysis, was associated with reduced mortality ( P = 0.043) and remained significant in a multivariable model. This study demonstrated that we obtained vancomycin trough levels in the target therapeutic range early during the course of therapy and that obtaining a higher vancomycin AUC/MIC (in this case, >373) within 96 h was associated with reduced mortality. The MIC test method has a significant impact on vancomycin AUC/MIC estimation. Clinicians should be aware that the current target AUC/MIC of ≥400 was derived using the reference BMD method, so adjustments to this target need to be made when calculating AUC/MIC ratio using other MIC testing methods.

1 August 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NHNatasha E. Holmes
Natasha E. Holmes
JTJohn D. Turnidge
John D. Turnidge
WMWendy J. Munckhof
Wendy J. Munckhof
JRJames O. Robinson
James O. Robinson
TKTony M. Korman
Tony M. Korman
BHBenjamin P. Howden
Benjamin P. Howden
(See the editorial commentary by Holland and Fowler Jr, on pages 329–31.)

1 May 2021 in Immunity
Verified
Journal Article
Closed access
TNThi Hoang Oanh Nguyen
Thi Hoang Oanh Nguyen
LRLouise C. Rowntree
Louise C. Rowntree
JPJan Petersen
Jan Petersen
BCBrendon Y. Chua
Brendon Y. Chua
LHLuca Hensen
Luca Hensen
KKKatherine Kedzierska
Katherine Kedzierska

23 August 2018 in Genome Medicine
Verified
Journal Article
Open access
PDF file
SGStefano G. Giulieri
Stefano G. Giulieri
SBSarah L Baines
Sarah L Baines
RGRomain Guerillot
Romain Guerillot
TSTorsten Seemann
Torsten Seemann
ASAnders Gonçalves da Silva
Anders Gonçalves da Silva
BHBenjamin P. Howden
Benjamin P. Howden
Large-scale genomic studies of within-host diversity in Staphylococcus aureus bacteraemia (SAB) are needed to understanding bacterial adaptation underlying persistence and thus refining the role of genomics in management of SAB. However, available comparative genomic studies of sequential SAB isolates have tended to focus on selected cases of unusually prolonged bacteraemia, where secondary antimicrobial resistance has developed. To understand bacterial genetic diversity during SAB more broadly, we applied whole genome sequencing to a large collection of sequential isolates obtained from patients with persistent or relapsing bacteraemia. After excluding genetically unrelated isolates, we performed an in-depth genomic analysis of point mutations and chromosome structural variants arising within individual SAB episodes. We show that, while adaptation pathways are heterogenous and episode-specific, isolates from persistent bacteraemia have a distinctive molecular signature, characterised by a low mutation frequency and high proportion of non-silent mutations. Analysis of structural genomic variants revealed that these often overlooked genetic events are commonly acquired during SAB. We discovered that IS256 insertion may represent the most effective driver of within-host microevolution in selected lineages, with up to three new insertion events per isolate even in the absence of other mutations. Genetic mechanisms resulting in significant phenotypic changes, such as increases in vancomycin resistance, development of small colony phenotypes, and decreases in cytotoxicity, included mutations in key genes (rpoB, stp, agrA) and an IS256 insertion upstream of the walKR operon. This study provides for the first time a large-scale analysis of within-host genomic changes during invasive S. aureus infection and describes specific patterns of adaptation that will be informative for both understanding S. aureus pathoadaptation and utilising genomics for management of complicated S. aureus infections.

29 August 2020 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
LALucy O. Attwood
Lucy O. Attwood
NHNatasha E. Holmes
Natasha E. Holmes
LHLisa Hui
Lisa Hui

11 December 2021 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
DFDanielle Fitzpatrick
Danielle Fitzpatrick
NHNatasha E. Holmes
Natasha E. Holmes
LHLisa Hui
Lisa Hui